GleamWall
中文EN

KLRS Kalaris Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1754068 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY21.8%
TTM EPS YoY90.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-97.2%
ROA-51.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets46.7%
Debt / equity0.00x
Current ratio10.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$30.75M$45.04M
SG&A expense$15.40M$6.69M
Operating income-$46.15M-$51.73M
Interest expense$1.44M$2.70M
Pretax income-$43.44M-$69.17M
Income tax$0$0
Net income-$43.44M-$69.17M
EBITDA-$46.14M—
EPS (basic)-2.85-51.77
EPS (diluted)-2.85-51.77
Weighted avg. shares (diluted)15.27M1.34M
Balance sheet
Cash & equivalents$98.05M$1.64M
Short-term investments$19.93M$0
Current assets$118.81M$2.61M
Total assets$121.74M$6.16M
Current liabilities$9.71M$24.70M
Total liabilities$42.92M$56.78M
Shareholders' equity$78.81M-$96.62M
Shares outstanding22.90M1.36M
Cash flow statement
Operating cash flow-$38.37M-$20.67M
Capital expenditure$200,000—
Free cash flow-$38.57M—
Investing cash flow-$19.72M$95.00M
Financing cash flow$155.01M$19.14M
Depreciation & amortization$13,000—
Stock-based compensation$1.94M$895,000

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.